Updates and advances in multiple sclerosis neurotherapeutics.

Abstract

The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding pipeline of agents with novel mechanisms, provide more options for patients with MS. While treatment of MS neuroinflammation is well tailored in the existing DMT armamentarium, concerted efforts are currently underway for identifying neuropathological targets and drug discovery for progressive MS. There is also ongoing research to develop agents for remyelination and neuroprotection. Further insights are needed to guide DMT initiation and sequencing as well as to determine the role of autologous stem cell transplantation in relapsing and progressive MS. This review provides a summary of these updates.

• Authors: Moein Amin, Carrie M Hersh
• Journal: Neurodegenerative disease management (Neurodegener Dis Manag) Vol. 13 Issue 1 Pg. 47-70 (02 2023) ISSN: 1758-2032 [Electronic] England
• PMID: 36314777 (Publication Type: Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Topics

• Humans
• Multiple Sclerosis (drug therapy)
• Hematopoietic Stem Cell Transplantation
• Transplantation, Autologous
• Multiple Sclerosis, Chronic Progressive
• Neuroprotection
• Multiple Sclerosis, Relapsing-Remitting (drug therapy)